Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.15 million
Profitability
Miscellaneous
Employees148
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) posted its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The firm earned $3.76 million during the quarter, compared to analyst estimates of $3.56 million. Cronos Group had a negative net margin of 45.72% and a negative return on equity of 3.22%. The firm's revenue for the quarter was up 187.0% on a year-over-year basis. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
4 brokers have issued 12 month price targets for Cronos Group's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Cronos Group's stock price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 39.6%. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
News stories about CRON stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cronos Group earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Tilray (TLRY), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Pharmacyte Biotech (PMCB), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN), FitLife Brands (FTLF) and Tauriga Sciences (TAUG).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 32)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.04%), USA Mutuals Advisors Inc. (0.04%) and First Command Bank (0.00%).
Which institutional investors are buying Cronos Group stock?
CRON stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, USA Mutuals Advisors Inc. and First Command Bank.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $14.90.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $2.42 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 148 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
